Join a clinical trial

Join a clinical trial

DSCF0018If you live with a respiratory illness, a clinical trial may give you access to new, innovative treatments as well as first-class care from a range of specialists.

Clinical trials are research studies involving people. They test ways to treat and prevent disease and are the gold standard tests for decisions on whether a treatment works and if it is more effective than an alternative treatment.

Below lists a number of clinical trials you may be eligible for. Each trial is different, so please read our FAQs to find out more.

For further information please contact our Clinical Trials Recruitment Officer, Alana at alana.perchard@resphealth.uwa.edu.au or phone 6457 3198.


Asthma

The study aims to evaluate the effectiveness and safety of Tezepelumab in patients with asthma.

  • Aged between 18-80 with a diagnosis of asthma made by a doctor
  • Use of two asthma inhalers daily
  • At least two asthma flare-ups in the last 12 months
  • Current smokers excluded

You will be required to attend up to 17 visits to Sir Charles Gairdner Hospital for approximately 16 months.

REGISTER

Asthma

The study aims to evaluate the effect of GSK3772847 in patients with moderately severe asthma.

  • Age 18 and above with a diagnosis of asthma
  • Use of a daily inhaled asthma medication
  • At least one flare up of your asthma in the last 12 months

You will be required to attend up to 14 visits to Sir Charles Gairdner Hospital for up to approximately 8 months.

REGISTER

Alpha1 Antitrypsin Deficiency

  • 18- 70 years old
  • Diagnosis of Alpha 1 Antitrypsin Deficiency with evidence of emphysema.
  • No flare up of the chest in the last 5 weeks prior to the first visit.
  • No cancer in last 5 years

You will be required to come once a week for 3 years for treatment including health checks to Sir Charles Gairdner Hospital.
CT scans of your lungs will be required on 5 occasions throughout the trial

REGISTER

Bronchiectasis

The study aims to evaluate the effect of INS1007 (study drug) compared with no study drug on time to first pulmonary exacerbation (chest flare up) over the 24-week treatment period.

  • Aged between 18 and 85 with a diagnosis of non-cystic fibrosis bronchiectasis.
  • At least two flare-ups of your bronchiectasis requiring antibiotic treatment in the last 12 months.

You will be required to attend up to 10 visits to Sir Charles Gairdner Hospital for up to approximately 8 months.

REGISTER

COPD

This study is to compare the effect of four different inhaled COPD medications on the rate of COPD exacerbations.

  • Aged 40 – 80 years old
  • Diagnosis of moderate to severe COPD
  • Current or former smoker
  • Use of two or more daily inhaled COPD therapies for at least the last six weeks
  • History of COPD exacerbation in the past 12 months

You will be required to attend a monthly visit to Sir Charles Gairdner Hospital for approximately a 12 month period.

REGISTER

IPF

The aim of this study is to evaluate the effect of CC-90001 in 200 mg tablet and 400 mg tablet, taken once daily compared with a placebo, on lung function after 24 weeks of treatment in patients with Idiopathic Pulmonary Fibrosis (IPF).

  • Aged 40 years or older
  • Have had a diagnosis of IPF within the last 4 years
  • Forced Vital Capacity (FVC) ≥45% at screening
  • Percent predicted diffusion capacity of the lung for carbon monoxide (DLCO) ≥ 30% and ≤ 85% predicted at Screening
  • Able to walk ≥150m during the 6-minute walk test at screening
  • Additional inclusion criteria apply

You will be required to attend a monthly visit to Sir Charles Gairdner Hospital for approximately 14 months. You will receive study treatment/placebo (2:1) in the form of oral tablets for approximately 52 weeks.

REGISTER

Pulmonary Arterial Hypertension

This study is to determine whether there are any health benefits to be gained from Apixaban, an anticoagulant medication, in patients with Systemic Sclerosis related Pulmonary Arterial Hypertension ( SSc – PAH) who are already prescribed advanced Pulmonary Arterial Hypertension (PAH) therapy.

  • Aged 18 – 75 years
  • Systemic Sclerosis related
  • Pulmonary Arterial Hypertension (SSc-PAH) diagnosed by a right heart catheterization

You will be required to attend at least 9 visits across a three year period at Sir Charles Gairdner Hospital. There are also monthly phone calls to assess any changes in your health.

REGISTER

Join a clinical trial was last modified: December 10th, 2018 by Sarah Cermak